Edesa Biotech, Inc.·4

May 29, 5:02 PM ET

MacDonald Sean Arthur 4

4 · Edesa Biotech, Inc. · Filed May 29, 2026

Research Summary

AI-generated summary of this filing

Updated

Edesa Biotech Director Sean MacDonald Receives 19,000‑Share Award

What Happened Sean Arthur MacDonald, a director of Edesa Biotech, Inc. (EDSA), received a grant of 19,000 restricted share units (RSUs) on 2026-05-27. The RSUs were reported at $0.00 per share (no cash purchase) — total reported acquisition value $0 — and are classified as an award/grant (A) on the Form 4.

Key Details

  • Transaction date: 2026-05-27; Form 4 filed: 2026-05-29 (appears timely).
  • Security: Restricted share units representing 19,000 shares; reported price: $0.00; total reported value: $0.
  • Vesting: Per footnote, the RSUs vest in equal proportions over 12 months beginning on the grant date.
  • Shares owned after transaction: Not specified in the provided filing excerpt.
  • Transaction type code: A = Award/Grant/Other acquisition.
  • No 10b5-1 plan, tax‑withholding, or sale noted in this filing.

Context This was a compensation award (RSUs) to a director rather than an open‑market purchase or sale. Such grants are common as part of director compensation and do not by themselves indicate buying/selling sentiment. The award vests over the next year, so the economic interest in underlying shares will accrue gradually as vesting occurs.

Insider Transaction Report

Form 4
Period: 2026-05-27
Transactions
  • Award

    Common Shares

    [F1]
    2026-05-27+19,00041,054 total
Footnotes (1)
  • [F1]Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.
Signature
/s/ Peter J. Weiler, Attorney-in-Fact for Sean Arthur MacDonald|2026-05-29

Documents

1 file
  • 4
    ownership.xmlPrimary